AlphaCitation reference lookup is an MCP server published by com.alphacitation, hosted at alphacitation.com. When last checked on 2026-11-22 it was working: it answers and lists its tools. It declares 4 tools, including check_drug_approval_fda_eu, lookup_medicine_evidence, read_drug_label_fda_eu, lookup_precedent_ruling.
Is a medicine approved in a market? US, EU/EEA regulators; others not settled. Not medical advice.
1,195 connections through 5 shared values. Tap any node.
Inferred from the host name and headers: what a server runs on, not who runs it.
Answers whether a drug or medicine is approved, authorised, licensed or registered in a country or in the EU (for example, whether it is FDA approved in the US), or approved there for a condition, today or on a past date, and which official record settles that. Records are held for the US (the FDA's approval record on Drugs@FDA for whether a medicine is approved, and the prescribing information on DailyMed, as submitted to the FDA, for what it is approved for) and, for centrally authorised medicines, for the EU and EEA (the European Commission's product information), and each answer resting on one carries its pointer URL. For any other market, the answer names that market's competent authority and where its registration record is published, each where it is identified, and says which is not; the claim is unresolved there, or supported, never settled, by the authorisation holder's own label. For one medicine, one market and one date, the answer gives which source settles whether the medicine is registered (P1) or authorised for an indication (P2), what that source says about the claim where its content has been checked, where this market's label differs from the US and EU labels, and what is unresolved. supported_attested means the authorisation holder's own approved label, read under the attestation conditions, states the claim; it never settles it. Where that label does not state the indication, or its content has not been checked, the answer is unresolved. An unresolved answer means AlphaCitation cannot currently verify the claim from a held record; it is not evidence about the medicine's status. Every answer that does not settle carries abstention, one reason code (insufficient_evidence, authority_inaccessible, conflicting_records, stale_evidence, unsupported_claim_type, snapshot_only) with its meaning.
Squares are this server's values; dots are other servers sharing them. A shared address or publisher is a lead, not proof of a common operator.
| Parameter | Type | Description |
|---|---|---|
| date | string | The date the claim is about, YYYY-MM-DD. Defaults to today (UTC). |
| market * | string | The market: an ISO 3166-1 alpha-2 code (US, AE, SA, DE) or EU. |
| medicine * | string | The brand or active substance name, exactly (for example Mounjaro or tirzepatide). |
| indication | string | Required for P2: one indication from the published list. allergic_fungal_rhinosinusitis: allergic fungal rhinosinusitis; alopecia_areata: alopecia areata; alveolar_soft_part_sarcoma: alveolar soft part sarcoma; ankylosing_spondylitis: ankylosing spondylitis (radiographic axial spondyloarthritis); as… |
| proposition * | string | P1: registered or authorised in the market. P2: authorised for an indication. |
| populationMinAgeYears | integer | Optional for P2: the youngest age the claim says the indication covers. |
{
"name": "check_drug_approval_fda_eu",
"title": "Is a drug FDA or EU approved?",
"description": "Answers whether a drug or medicine is approved, authorised, licensed or registered in a country or in the EU (for example, whether it is FDA approved in the US), or approved there for a condition, today or on a past date, and which official record settles that. Records are held for the US (the FDA's approval record on Drugs@FDA for whether a medicine is approved, and the prescribing information on DailyMed, as submitted to the FDA, for what it is approved for) and, for centrally authorised medicines, for the EU and EEA (the European Commission's product information), and each answer resting on one carries its pointer URL. For any other market, the answer names that market's competent authority and where its registration record is published, each where it is identified, and says which is not; the claim is unresolved there, or supported, never settled, by the authorisation holder's own label. For one medicine, one market and one date, the answer gives which source settles whether the medicine is registered (P1) or authorised for an indication (P2), what that source says about the claim where its content has been checked, where this market's label differs from the US and EU labels, and what is unresolved. supported_attested means the authorisation holder's own approved label, read under the attestation conditions, states the claim; it never settles it. Where that label does not state the indication, or its content has not been checked, the answer is unresolved. An unresolved answer means AlphaCitation cannot currently verify the claim from a held record; it is not evidence about the medicine's status. Every answer that does not settle carries abstention, one reason code (insufficient_evidence, authority_inaccessible, conflicting_records, stale_evidence, unsupported_claim_type, snapshot_only) with its meaning.",
"inputSchema": {
"type": "object",
"required": [
"medicine",
"market",
"proposition"
],
"properties": {
"date": {
"type": "string",
"description": "The date the claim is about, YYYY-MM-DD. Defaults to today (UTC)."
},
"market": {
"type": "string",
"description": "The market: an ISO 3166-1 alpha-2 code (US, AE, SA, DE) or EU."
},
"medicine": {
"type": "string",
"description": "The brand or active substance name, exactly (for example Mounjaro or tirzepatide)."
},
"indication": {
"enum": [
"allergic_fungal_rhinosinusitis",
"alopecia_areata",
"alveolar_soft_part_sarcoma",
"ankylosing_spondylitis",
"asthma",
"asthma_moderate_to_severe_add_on_type2_eosinophilic",
"atopic_dermatitis",
"atopic_dermatitis_moderate_to_severe_systemic_candidates",
"atypical_haemolytic_uraemic_syndrome",
"basal_cell_carcinoma",
"biliary_tract_cancer",
"breast_cancer",
"breast_her2_low_metastatic",
"breast_her2_positive_metastatic",
"breast_her2_positive_metastatic_first_line_pertuzumab",
"breast_her2_positive_neoadjuvant",
"breast_hr_pos_her2_neg_adjuvant_aromatase_inhibitor_lhrh",
"breast_hr_pos_her2_neg_metastatic_initial_endocrine_ai_lhrh",
"breast_hr_positive_her2_negative_adjuvant",
"breast_hr_positive_her2_negative_adjuvant_aromatase_inhibitor",
"breast_hr_positive_her2_negative_metastatic",
"breast_hr_positive_her2_negative_metastatic_aromatase_inhibitor",
"breast_hr_positive_her2_negative_metastatic_initial_endocrine_ai",
"breast_hr_positive_her2_ultralow_metastatic",
"bullous_pemphigoid",
"c3_glomerulopathy",
"cervical_cancer",
"chronic_inflammatory_demyelinating_polyneuropathy",
"chronic_obstructive_pulmonary_disease",
"chronic_rhinosinusitis_with_nasal_polyps",
"chronic_spontaneous_urticaria",
"classical_hodgkin_lymphoma",
"colon_cancer",
"colorectal_cancer",
"crc_msi_h_dmmr_metastatic_first_line_monotherapy",
"crohns_disease",
"crohns_disease_moderately_to_severely_active",
"cutaneous_squamous_cell_carcinoma",
"cv_risk_reduction_obesity",
"dmd_ambulatory",
"dmd_ambulatory_confirmed_mutation",
"dmd_non_ambulatory",
"dmd_non_ambulatory_confirmed_mutation",
"duchenne_muscular_dystrophy",
"early_alzheimers_disease",
"early_alzheimers_disease_amyloid_confirmed",
"early_alzheimers_disease_apoe4_noncarrier_or_heterozygote",
"endometrial_carcinoma",
"endometrial_msi_h_dmmr_previously_treated_monotherapy",
"endometrial_pmmr_previously_treated_with_lenvatinib",
"enthesitis_related_arthritis",
"eosinophilic_oesophagitis",
"gastric_cancer",
"gastric_her2_negative_first_line_with_chemotherapy_pdl1_cps_1",
"gastric_her2_negative_first_line_with_chemotherapy_pdl1_tap_5",
"generalised_myasthenia_gravis",
"giant_cell_arteritis",
"gmg_achr_antibody_positive",
"gmg_achr_antibody_positive_add_on_standard_therapy",
"gmg_musk_antibody_positive",
"gmg_musk_antibody_positive_add_on_standard_therapy",
"gmg_seronegative",
"hcc_first_line_with_ipilimumab",
"head_and_neck_squamous_cell_carcinoma",
"hepatocellular_carcinoma",
"her2_positive_solid_tumours",
"hidradenitis_suppurativa",
"hnscc_metastatic_first_line_monotherapy_pdl1_cps_1",
"iga_nephropathy",
"immune_complex_mpgn",
"malignant_pleural_mesothelioma",
"mash_with_fibrosis",
"melanoma",
"melanoma_adjuvant",
"melanoma_metastatic",
"melanoma_metastatic_with_ipilimumab",
"merkel_cell_carcinoma",
"msi_h_dmmr_solid_tumours",
"nasopharyngeal_carcinoma",
"neuromyelitis_optica_spectrum_disorder",
"non_radiographic_axial_spondyloarthritis",
"non_small_cell_lung_cancer",
"nsclc_adjuvant",
"nsclc_advanced_first_line_monotherapy_platinum_ineligible",
"nsclc_early_stage_monotherapy",
"nsclc_metastatic_after_platinum_monotherapy",
"nsclc_metastatic_first_line_monotherapy_pdl1_cps_1",
"nsclc_metastatic_first_line_monotherapy_pdl1_ic_10",
"nsclc_metastatic_first_line_monotherapy_pdl1_tps_1",
"nsclc_metastatic_first_line_monotherapy_pdl1_tps_50",
"nsclc_metastatic_first_line_nonsquamous_with_chemotherapy",
"nsclc_metastatic_first_line_squamous_with_chemotherapy",
"nsclc_metastatic_first_line_with_chemotherapy_pdl1_below_1",
"nsclc_metastatic_first_line_with_chemotherapy_pdl1_tps_1",
"nsclc_metastatic_first_line_with_ipilimumab_pdl1",
"nsclc_metastatic_with_tremelimumab_alone",
"nsclc_metastatic_with_tremelimumab_and_chemotherapy",
"nsclc_monotherapy_pdl1_below_1",
"nsclc_resectable_large_or_node_positive_adjuvant_monotherapy",
"nsclc_resectable_large_or_node_positive_neoadjuvant_chemotherapy",
"nsclc_resectable_large_or_node_positive_perioperative",
"nsclc_resectable_small_node_negative_perioperative",
"nsclc_unresectable_stage_iii_monotherapy_after_chemoradiation",
"oesophageal_cancer",
"osa_with_obesity",
"ovarian_cancer",
"paroxysmal_nocturnal_haemoglobinuria",
"plaque_psoriasis",
"plaque_psoriasis_moderate_to_severe_systemic_candidates",
"polyarticular_juvenile_idiopathic_arthritis",
"primary_mediastinal_large_b_cell_lymphoma",
"prurigo_nodularis",
"psoriatic_arthritis",
"psoriatic_arthritis_active",
"rcc_adjuvant_monotherapy",
"rcc_advanced_first_line_with_axitinib",
"rcc_advanced_first_line_with_lenvatinib",
"renal_cell_carcinoma",
"rheumatoid_arthritis",
"rheumatoid_arthritis_moderately_to_severely_active",
"scd_recurrent_vaso_occlusive_crises",
"sclc_extensive_stage",
"sclc_limited_stage",
"sickle_cell_disease",
"small_cell_lung_cancer",
"small_intestine_cancer",
"t2dm_ckd_risk_reduction",
"t2dm_cv_risk_reduction",
"t2dm_glycaemic_control",
"tmb_h_solid_tumours",
"tmb_h_solid_tumours_cns",
"tmb_h_solid_tumours_ge10",
"tmb_h_solid_tumours_ge13",
"tmb_solid_tumours_patient_10_to_12",
"tnbc_metastatic_first_line",
"tnbc_metastatic_first_line_pembrolizumab_pdl1_cps_10",
"tnbc_metastatic_previously_treated",
"transfusion_dependent_beta_thalassaemia",
"triple_negative_breast_cancer",
"ulcerative_colitis",
"ulcerative_colitis_moderately_to_severely_active",
"urothelial_carcinoma",
"urothelial_metastatic_with_enfortumab_vedotin",
"uveitis",
"vitiligo",
"warm_autoimmune_haemolytic_anaemia",
"weight_management"
],
"type": "string",
"description": "Required for P2: one indication from the published list. allergic_fungal_rhinosinusitis: allergic fungal rhinosinusitis; alopecia_areata: alopecia areata; alveolar_soft_part_sarcoma: alveolar soft part sarcoma; ankylosing_spondylitis: ankylosing spondylitis (radiographic axial spondyloarthritis); asthma: asthma; asthma_moderate_to_severe_add_on_type2_eosinophilic: add-on maintenance treatment of moderate-to-severe asthma, type 2 or eosinophilic phenotype; atopic_dermatitis: atopic dermatitis; atopic_dermatitis_moderate_to_severe_systemic_candidates: moderate-to-severe atopic dermatitis in candidates for systemic therapy; atypical_haemolytic_uraemic_syndrome: atypical haemolytic uraemic syndrome (aHUS); basal_cell_carcinoma: basal cell carcinoma; biliary_tract_cancer: biliary tract cancer; breast_cancer: breast cancer; breast_her2_low_metastatic: metastatic HER2-low breast cancer; breast_her2_positive_metastatic: metastatic HER2-positive breast cancer; breast_her2_positive_metastatic_first_line_pertuzumab: first-line metastatic HER2-positive breast cancer, in combination with pertuzumab; breast_her2_positive_neoadjuvant: neoadjuvant treatment of HER2-positive breast cancer; breast_hr_pos_her2_neg_adjuvant_aromatase_inhibitor_lhrh: adjuvant HR-positive, HER2-negative early breast cancer: aromatase inhibitor with an LHRH agonist; breast_hr_pos_her2_neg_metastatic_initial_endocrine_ai_lhrh: metastatic HR-positive, HER2-negative breast cancer: aromatase inhibitor, initial endocrine therapy, LHRH agonist; breast_hr_positive_her2_negative_adjuvant: adjuvant treatment of HR-positive, HER2-negative early breast cancer; breast_hr_positive_her2_negative_adjuvant_aromatase_inhibitor: adjuvant treatment of HR-positive, HER2-negative early breast cancer, with an aromatase inhibitor; breast_hr_positive_her2_negative_metastatic: metastatic hormone receptor-positive, HER2-negative breast cancer; breast_hr_positive_her2_negative_metastatic_aromatase_inhibitor: metastatic HR-positive, HER2-negative breast cancer, with an aromatase inhibitor; breast_hr_positive_her2_negative_metastatic_initial_endocrine_ai: metastatic HR-positive, HER2-negative breast cancer, with an aromatase inhibitor as initial endocrine-based therapy; breast_hr_positive_her2_ultralow_metastatic: metastatic hormone receptor-positive, HER2-ultralow breast cancer; bullous_pemphigoid: bullous pemphigoid; c3_glomerulopathy: C3 glomerulopathy (C3G); cervical_cancer: cervical cancer; chronic_inflammatory_demyelinating_polyneuropathy: chronic inflammatory demyelinating polyneuropathy (CIDP); chronic_obstructive_pulmonary_disease: chronic obstructive pulmonary disease (COPD); chronic_rhinosinusitis_with_nasal_polyps: chronic rhinosinusitis with nasal polyps; chronic_spontaneous_urticaria: chronic spontaneous urticaria; classical_hodgkin_lymphoma: classical Hodgkin lymphoma; colon_cancer: colon cancer; colorectal_cancer: colorectal cancer; crc_msi_h_dmmr_metastatic_first_line_monotherapy: first-line metastatic MSI-H or dMMR colorectal cancer, monotherapy; crohns_disease: Crohn’s disease; crohns_disease_moderately_to_severely_active: moderately to severely active Crohn’s disease; cutaneous_squamous_cell_carcinoma: cutaneous squamous cell carcinoma; cv_risk_reduction_obesity: reducing the risk of major adverse cardiovascular events; dmd_ambulatory: Duchenne muscular dystrophy, ambulatory patients; dmd_ambulatory_confirmed_mutation: Duchenne muscular dystrophy with a confirmed mutation in the DMD gene, ambulatory patients; dmd_non_ambulatory: Duchenne muscular dystrophy, non-ambulatory patients; dmd_non_ambulatory_confirmed_mutation: Duchenne muscular dystrophy with a confirmed mutation in the DMD gene, non-ambulatory patients; duchenne_muscular_dystrophy: Duchenne muscular dystrophy (DMD); early_alzheimers_disease: early Alzheimer’s disease (mild cognitive impairment or mild dementia stage); early_alzheimers_disease_amyloid_confirmed: early Alzheimer’s disease with confirmed amyloid pathology; early_alzheimers_disease_apoe4_noncarrier_or_heterozygote: early Alzheimer’s disease in ApoE ε4 non-carriers or heterozygotes, amyloid confirmed; endometrial_carcinoma: endometrial carcinoma; endometrial_msi_h_dmmr_previously_treated_monotherapy: advanced MSI-H or dMMR endometrial carcinoma after prior therapy, monotherapy; endometrial_pmmr_previously_treated_with_lenvatinib: advanced pMMR or non-MSI-H endometrial carcinoma after prior therapy, with lenvatinib; enthesitis_related_arthritis: enthesitis-related arthritis; eosinophilic_oesophagitis: eosinophilic oesophagitis; gastric_cancer: gastric or gastro-oesophageal junction cancer; gastric_her2_negative_first_line_with_chemotherapy_pdl1_cps_1: first-line HER2-negative gastric or GEJ adenocarcinoma, with chemotherapy, PD-L1 CPS at least 1; gastric_her2_negative_first_line_with_chemotherapy_pdl1_tap_5: first-line HER2-negative gastric or GEJ adenocarcinoma, with chemotherapy, PD-L1 TAP score at least 5%; generalised_myasthenia_gravis: generalised myasthenia gravis (gMG); giant_cell_arteritis: giant cell arteritis; gmg_achr_antibody_positive: generalised myasthenia gravis, anti-AChR antibody-positive; gmg_achr_antibody_positive_add_on_standard_therapy: gMG, anti-AChR antibody-positive, as an add-on to standard therapy; gmg_musk_antibody_positive: generalised myasthenia gravis, anti-MuSK antibody-positive; gmg_musk_antibody_positive_add_on_standard_therapy: gMG, anti-MuSK antibody-positive, as an add-on to standard therapy; gmg_seronegative: generalised myasthenia gravis, seronegative (neither anti-AChR nor anti-MuSK antibody-positive); hcc_first_line_with_ipilimumab: first-line unresectable or advanced hepatocellular carcinoma, with ipilimumab; head_and_neck_squamous_cell_carcinoma: head and neck squamous cell carcinoma; hepatocellular_carcinoma: hepatocellular carcinoma; her2_positive_solid_tumours: HER2-positive solid tumours (tumour-agnostic); hidradenitis_suppurativa: hidradenitis suppurativa; hnscc_metastatic_first_line_monotherapy_pdl1_cps_1: first-line metastatic HNSCC, monotherapy, PD-L1 CPS at least 1; iga_nephropathy: immunoglobulin A nephropathy (IgAN); immune_complex_mpgn: primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN); malignant_pleural_mesothelioma: malignant pleural mesothelioma; mash_with_fibrosis: metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis; melanoma: melanoma; melanoma_adjuvant: adjuvant treatment of resected melanoma; melanoma_metastatic: metastatic melanoma; melanoma_metastatic_with_ipilimumab: metastatic melanoma, in combination with ipilimumab; merkel_cell_carcinoma: Merkel cell carcinoma; msi_h_dmmr_solid_tumours: MSI-H or dMMR solid tumours (tumour-agnostic); nasopharyngeal_carcinoma: nasopharyngeal carcinoma; neuromyelitis_optica_spectrum_disorder: neuromyelitis optica spectrum disorder (NMOSD); non_radiographic_axial_spondyloarthritis: non-radiographic axial spondyloarthritis; non_small_cell_lung_cancer: non-small cell lung cancer (NSCLC); nsclc_adjuvant: adjuvant treatment of resected NSCLC; nsclc_advanced_first_line_monotherapy_platinum_ineligible: first-line advanced NSCLC, monotherapy, ineligible for platinum-based therapy; nsclc_early_stage_monotherapy: early-stage NSCLC, monotherapy; nsclc_metastatic_after_platinum_monotherapy: metastatic NSCLC after platinum-containing chemotherapy, monotherapy; nsclc_metastatic_first_line_monotherapy_pdl1_cps_1: first-line metastatic NSCLC, monotherapy, PD-L1 combined positive score at least 1, no EGFR or ALK aberration; nsclc_metastatic_first_line_monotherapy_pdl1_ic_10: first-line metastatic NSCLC, monotherapy, PD-L1 immune cell score at least 10%, no EGFR or ALK aberration; nsclc_metastatic_first_line_monotherapy_pdl1_tps_1: first-line metastatic NSCLC, monotherapy, PD-L1 TPS at least 1%, no EGFR or ALK aberration; nsclc_metastatic_first_line_monotherapy_pdl1_tps_50: first-line metastatic NSCLC, monotherapy, PD-L1 TPS at least 50%, no EGFR or ALK aberration; nsclc_metastatic_first_line_nonsquamous_with_chemotherapy: first-line metastatic non-squamous NSCLC, with chemotherapy, no EGFR or ALK aberration; nsclc_metastatic_first_line_squamous_with_chemotherapy: first-line metastatic squamous NSCLC, with chemotherapy; nsclc_metastatic_first_line_with_chemotherapy_pdl1_below_1: first-line metastatic NSCLC, with chemotherapy, PD-L1 tumour proportion score below 1%, no EGFR or ALK aberration; nsclc_metastatic_first_line_with_chemotherapy_pdl1_tps_1: first-line metastatic NSCLC, with chemotherapy, PD-L1 tumour proportion score at least 1%, no EGFR or ALK aberration; nsclc_metastatic_first_line_with_ipilimumab_pdl1: first-line metastatic NSCLC, with ipilimumab, PD-L1 at least 1%, no EGFR or ALK aberration; nsclc_metastatic_with_tremelimumab_alone: metastatic NSCLC, with tremelimumab and no chemotherapy; nsclc_metastatic_with_tremelimumab_and_chemotherapy: metastatic NSCLC, with tremelimumab and platinum-based chemotherapy, no EGFR or ALK aberration; nsclc_monotherapy_pdl1_below_1: unresectable locally advanced NSCLC, monotherapy, PD-L1 tumour proportion score below 1%; nsclc_resectable_large_or_node_positive_adjuvant_monotherapy: resectable NSCLC of at least 4 cm and/or node positive, adjuvant single agent alone; nsclc_resectable_large_or_node_positive_neoadjuvant_chemotherapy: resectable NSCLC of at least 4 cm and/or node positive, neoadjuvant chemotherapy alone; nsclc_resectable_large_or_node_positive_perioperative: resectable NSCLC of at least 4 cm and/or node positive, perioperative, no EGFR or ALK aberration; nsclc_resectable_small_node_negative_perioperative: resectable NSCLC under 4 cm and node negative, neoadjuvant chemotherapy then adjuvant single agent; nsclc_unresectable_stage_iii_monotherapy_after_chemoradiation: unresectable stage III NSCLC, monotherapy, disease not progressed after platinum-based chemoradiation; oesophageal_cancer: oesophageal cancer; osa_with_obesity: obstructive sleep apnoea; ovarian_cancer: ovarian, fallopian tube or primary peritoneal cancer; paroxysmal_nocturnal_haemoglobinuria: paroxysmal nocturnal haemoglobinuria (PNH); plaque_psoriasis: plaque psoriasis; plaque_psoriasis_moderate_to_severe_systemic_candidates: moderate-to-severe plaque psoriasis in candidates for systemic therapy; polyarticular_juvenile_idiopathic_arthritis: polyarticular juvenile idiopathic arthritis; primary_mediastinal_large_b_cell_lymphoma: primary mediastinal large B-cell lymphoma; prurigo_nodularis: prurigo nodularis; psoriatic_arthritis: psoriatic arthritis; psoriatic_arthritis_active: active psoriatic arthritis; rcc_adjuvant_monotherapy: adjuvant treatment of renal cell carcinoma after nephrectomy, monotherapy; rcc_advanced_first_line_with_axitinib: first-line advanced renal cell carcinoma, with axitinib; rcc_advanced_first_line_with_lenvatinib: first-line advanced renal cell carcinoma, with lenvatinib; renal_cell_carcinoma: renal cell carcinoma; rheumatoid_arthritis: rheumatoid arthritis; rheumatoid_arthritis_moderately_to_severely_active: moderately to severely active rheumatoid arthritis; scd_recurrent_vaso_occlusive_crises: sickle cell disease with recurrent vaso-occlusive crises; sclc_extensive_stage: extensive-stage small cell lung cancer; sclc_limited_stage: limited-stage small cell lung cancer; sickle_cell_disease: sickle cell disease (SCD); small_cell_lung_cancer: small cell lung cancer; small_intestine_cancer: small intestine cancer; t2dm_ckd_risk_reduction: reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death; t2dm_cv_risk_reduction: reducing the risk of major adverse cardiovascular events; t2dm_glycaemic_control: glycaemic control in type 2 diabetes; tmb_h_solid_tumours: TMB-H solid tumours (tumour-agnostic); tmb_h_solid_tumours_cns: TMB-H solid tumours that are central nervous system cancers; tmb_h_solid_tumours_ge10: TMB-H solid tumours at 10 or more mutations per megabase; tmb_h_solid_tumours_ge13: TMB-H solid tumours at 13 or more mutations per megabase; tmb_solid_tumours_patient_10_to_12: a solid tumour with 10 to 12 mutations per megabase; tnbc_metastatic_first_line: first-line metastatic triple-negative breast cancer; tnbc_metastatic_first_line_pembrolizumab_pdl1_cps_10: first-line metastatic TNBC, with pembrolizumab, PD-L1 CPS at least 10; tnbc_metastatic_previously_treated: previously treated metastatic triple-negative breast cancer; transfusion_dependent_beta_thalassaemia: transfusion-dependent beta-thalassaemia (TDT); triple_negative_breast_cancer: triple-negative breast cancer; ulcerative_colitis: ulcerative colitis; ulcerative_colitis_moderately_to_severely_active: moderately to severely active ulcerative colitis; urothelial_carcinoma: urothelial carcinoma, including bladder cancer; urothelial_metastatic_with_enfortumab_vedotin: metastatic urothelial carcinoma, with enfortumab vedotin; uveitis: non-infectious uveitis; vitiligo: vitiligo; warm_autoimmune_haemolytic_anaemia: warm autoimmune haemolytic anaemia (wAIHA); weight_management: weight management."
},
"proposition": {
"enum": [
"P1",
"P2"
],
"type": "string",
"description": "P1: registered or authorised in the market. P2: authorised for an indication."
},
"populationMinAgeYears": {
"type": "integer",
"maximum": 120,
"minimum": 0,
"description": "Optional for P2: the youngest age the claim says the indication covers."
}
},
"additionalProperties": false
},
"outputSchema": {
"type": "object",
"required": [
"status",
"relation",
"summary",
"records",
"unresolved",
"scope"
],
"properties": {
"notes": {
"type": "array"
},
"scope": {
"type": "object"
},
"status": {
"enum": [
"settled",
"settling_record_identified",
"supported_attested",
"reference_only",
"unresolved"
],
"type": "string"
},
"records": {
"type": "array"
},
"summary": {
"type": "string"
},
"relation": {
"enum": [
"agrees",
"agrees_narrower",
"disagrees",
"insufficient"
],
"type": "string"
},
"abstention": {
"type": [
"object",
"null"
],
"properties": {
"code": {
"enum": [
"insufficient_evidence",
"authority_inaccessible",
"conflicting_records",
"stale_evidence",
"unsupported_claim_type",
"snapshot_only"
],
"type": "string"
},
"route": {
"enum": [
"search_further",
"retry_later",
"request_human_review",
"stop"
],
"type": "string"
},
"meaning": {
"type": "string"
}
},
"description": "Null when settled. Otherwise one reason code: insufficient_evidence (route search_further): No held record settles the claim for this market and date. authority_inaccessible (route retry_later): The record that would decide the claim could not be read just now; retryAfter gives when it may be read. conflicting_records (route request_human_review): Records held disagree about the claim. stale_evidence (route search_further): The evidence held is out of date for the date asked. unsupported_claim_type (route stop): The claim is not one this service assesses: its market, proposition or indication is not supported. snapshot_only (route search_further): A past authoritative capture is held, but the current record is not confirmed."
},
"comparison": {
"type": "array"
},
"inspection": {
"type": "object"
},
"unresolved": {
"type": "array"
},
"indicationScope": {
"type": [
"object",
"null"
],
"description": "Where the regulator recorded that a use is not a separate indication, though its benefit is stated in the product information and the use is covered by an existing indication: the three apart, with the document."
},
"competentAuthorities": {
"type": "array"
}
}
},
"annotations": {
"title": "Is a drug FDA or EU approved?",
"readOnlyHint": true,
"openWorldHint": true,
"idempotentHint": true,
"destructiveHint": false
}
}Answers whether a drug or medicine is approved, authorised, licensed or registered in a country or in the EU (for example, whether it is FDA approved in the US), or approved there for a condition, today or on a past date, and which official record settles that. Records are held for the US (the FDA's approval record on Drugs@FDA for whether a medicine is approved, and the prescribing information on DailyMed, as submitted to the FDA, for what it is approved for) and, for centrally authorised medicines, for the EU and EEA (the European Commission's product information), and each answer resting on one carries its pointer URL. For any other market, the answer names that market's competent authority and where its registration record is published, each where it is identified, and says which is not; the claim is unresolved there, or supported, never settled, by the authorisation holder's own label. For one medicine, one market and one date, the answer gives which source settles whether the medicine is registered (P1) or authorised for an indication (P2), what that source says about the claim where its content has been checked, where this market's label differs from the US and EU labels, and what is unresolved. supported_attested means the authorisation holder's own approved label, read under the attestation conditions, states the claim; it never settles it. Where that label does not state the indication, or its content has not been checked, the answer is unresolved. An unresolved answer means AlphaCitation cannot currently verify the claim from a held record; it is not evidence about the medicine's status. Every answer that does not settle carries abstention, one reason code (insufficient_evidence, authority_inaccessible, conflicting_records, stale_evidence, unsupported_claim_type, snapshot_only) with its meaning.
| Parameter | Type | Description |
|---|---|---|
| date | string | The date the claim is about, YYYY-MM-DD. Defaults to today (UTC). |
| market * | string | The market: an ISO 3166-1 alpha-2 code (US, AE, SA, DE) or EU. |
| medicine * | string | The brand or active substance name, exactly (for example Mounjaro or tirzepatide). |
| indication | string | Required for P2: one indication from the published list. allergic_fungal_rhinosinusitis: allergic fungal rhinosinusitis; alopecia_areata: alopecia areata; alveolar_soft_part_sarcoma: alveolar soft part sarcoma; ankylosing_spondylitis: ankylosing spondylitis (radiographic axial spondyloarthritis); as… |
| proposition * | string | P1: registered or authorised in the market. P2: authorised for an indication. |
| populationMinAgeYears | integer | Optional for P2: the youngest age the claim says the indication covers. |
{
"name": "lookup_medicine_evidence",
"title": "Is a medicine approved in a market?",
"description": "Answers whether a drug or medicine is approved, authorised, licensed or registered in a country or in the EU (for example, whether it is FDA approved in the US), or approved there for a condition, today or on a past date, and which official record settles that. Records are held for the US (the FDA's approval record on Drugs@FDA for whether a medicine is approved, and the prescribing information on DailyMed, as submitted to the FDA, for what it is approved for) and, for centrally authorised medicines, for the EU and EEA (the European Commission's product information), and each answer resting on one carries its pointer URL. For any other market, the answer names that market's competent authority and where its registration record is published, each where it is identified, and says which is not; the claim is unresolved there, or supported, never settled, by the authorisation holder's own label. For one medicine, one market and one date, the answer gives which source settles whether the medicine is registered (P1) or authorised for an indication (P2), what that source says about the claim where its content has been checked, where this market's label differs from the US and EU labels, and what is unresolved. supported_attested means the authorisation holder's own approved label, read under the attestation conditions, states the claim; it never settles it. Where that label does not state the indication, or its content has not been checked, the answer is unresolved. An unresolved answer means AlphaCitation cannot currently verify the claim from a held record; it is not evidence about the medicine's status. Every answer that does not settle carries abstention, one reason code (insufficient_evidence, authority_inaccessible, conflicting_records, stale_evidence, unsupported_claim_type, snapshot_only) with its meaning.",
"inputSchema": {
"type": "object",
"required": [
"medicine",
"market",
"proposition"
],
"properties": {
"date": {
"type": "string",
"description": "The date the claim is about, YYYY-MM-DD. Defaults to today (UTC)."
},
"market": {
"type": "string",
"description": "The market: an ISO 3166-1 alpha-2 code (US, AE, SA, DE) or EU."
},
"medicine": {
"type": "string",
"description": "The brand or active substance name, exactly (for example Mounjaro or tirzepatide)."
},
"indication": {
"enum": [
"allergic_fungal_rhinosinusitis",
"alopecia_areata",
"alveolar_soft_part_sarcoma",
"ankylosing_spondylitis",
"asthma",
"asthma_moderate_to_severe_add_on_type2_eosinophilic",
"atopic_dermatitis",
"atopic_dermatitis_moderate_to_severe_systemic_candidates",
"atypical_haemolytic_uraemic_syndrome",
"basal_cell_carcinoma",
"biliary_tract_cancer",
"breast_cancer",
"breast_her2_low_metastatic",
"breast_her2_positive_metastatic",
"breast_her2_positive_metastatic_first_line_pertuzumab",
"breast_her2_positive_neoadjuvant",
"breast_hr_pos_her2_neg_adjuvant_aromatase_inhibitor_lhrh",
"breast_hr_pos_her2_neg_metastatic_initial_endocrine_ai_lhrh",
"breast_hr_positive_her2_negative_adjuvant",
"breast_hr_positive_her2_negative_adjuvant_aromatase_inhibitor",
"breast_hr_positive_her2_negative_metastatic",
"breast_hr_positive_her2_negative_metastatic_aromatase_inhibitor",
"breast_hr_positive_her2_negative_metastatic_initial_endocrine_ai",
"breast_hr_positive_her2_ultralow_metastatic",
"bullous_pemphigoid",
"c3_glomerulopathy",
"cervical_cancer",
"chronic_inflammatory_demyelinating_polyneuropathy",
"chronic_obstructive_pulmonary_disease",
"chronic_rhinosinusitis_with_nasal_polyps",
"chronic_spontaneous_urticaria",
"classical_hodgkin_lymphoma",
"colon_cancer",
"colorectal_cancer",
"crc_msi_h_dmmr_metastatic_first_line_monotherapy",
"crohns_disease",
"crohns_disease_moderately_to_severely_active",
"cutaneous_squamous_cell_carcinoma",
"cv_risk_reduction_obesity",
"dmd_ambulatory",
"dmd_ambulatory_confirmed_mutation",
"dmd_non_ambulatory",
"dmd_non_ambulatory_confirmed_mutation",
"duchenne_muscular_dystrophy",
"early_alzheimers_disease",
"early_alzheimers_disease_amyloid_confirmed",
"early_alzheimers_disease_apoe4_noncarrier_or_heterozygote",
"endometrial_carcinoma",
"endometrial_msi_h_dmmr_previously_treated_monotherapy",
"endometrial_pmmr_previously_treated_with_lenvatinib",
"enthesitis_related_arthritis",
"eosinophilic_oesophagitis",
"gastric_cancer",
"gastric_her2_negative_first_line_with_chemotherapy_pdl1_cps_1",
"gastric_her2_negative_first_line_with_chemotherapy_pdl1_tap_5",
"generalised_myasthenia_gravis",
"giant_cell_arteritis",
"gmg_achr_antibody_positive",
"gmg_achr_antibody_positive_add_on_standard_therapy",
"gmg_musk_antibody_positive",
"gmg_musk_antibody_positive_add_on_standard_therapy",
"gmg_seronegative",
"hcc_first_line_with_ipilimumab",
"head_and_neck_squamous_cell_carcinoma",
"hepatocellular_carcinoma",
"her2_positive_solid_tumours",
"hidradenitis_suppurativa",
"hnscc_metastatic_first_line_monotherapy_pdl1_cps_1",
"iga_nephropathy",
"immune_complex_mpgn",
"malignant_pleural_mesothelioma",
"mash_with_fibrosis",
"melanoma",
"melanoma_adjuvant",
"melanoma_metastatic",
"melanoma_metastatic_with_ipilimumab",
"merkel_cell_carcinoma",
"msi_h_dmmr_solid_tumours",
"nasopharyngeal_carcinoma",
"neuromyelitis_optica_spectrum_disorder",
"non_radiographic_axial_spondyloarthritis",
"non_small_cell_lung_cancer",
"nsclc_adjuvant",
"nsclc_advanced_first_line_monotherapy_platinum_ineligible",
"nsclc_early_stage_monotherapy",
"nsclc_metastatic_after_platinum_monotherapy",
"nsclc_metastatic_first_line_monotherapy_pdl1_cps_1",
"nsclc_metastatic_first_line_monotherapy_pdl1_ic_10",
"nsclc_metastatic_first_line_monotherapy_pdl1_tps_1",
"nsclc_metastatic_first_line_monotherapy_pdl1_tps_50",
"nsclc_metastatic_first_line_nonsquamous_with_chemotherapy",
"nsclc_metastatic_first_line_squamous_with_chemotherapy",
"nsclc_metastatic_first_line_with_chemotherapy_pdl1_below_1",
"nsclc_metastatic_first_line_with_chemotherapy_pdl1_tps_1",
"nsclc_metastatic_first_line_with_ipilimumab_pdl1",
"nsclc_metastatic_with_tremelimumab_alone",
"nsclc_metastatic_with_tremelimumab_and_chemotherapy",
"nsclc_monotherapy_pdl1_below_1",
"nsclc_resectable_large_or_node_positive_adjuvant_monotherapy",
"nsclc_resectable_large_or_node_positive_neoadjuvant_chemotherapy",
"nsclc_resectable_large_or_node_positive_perioperative",
"nsclc_resectable_small_node_negative_perioperative",
"nsclc_unresectable_stage_iii_monotherapy_after_chemoradiation",
"oesophageal_cancer",
"osa_with_obesity",
"ovarian_cancer",
"paroxysmal_nocturnal_haemoglobinuria",
"plaque_psoriasis",
"plaque_psoriasis_moderate_to_severe_systemic_candidates",
"polyarticular_juvenile_idiopathic_arthritis",
"primary_mediastinal_large_b_cell_lymphoma",
"prurigo_nodularis",
"psoriatic_arthritis",
"psoriatic_arthritis_active",
"rcc_adjuvant_monotherapy",
"rcc_advanced_first_line_with_axitinib",
"rcc_advanced_first_line_with_lenvatinib",
"renal_cell_carcinoma",
"rheumatoid_arthritis",
"rheumatoid_arthritis_moderately_to_severely_active",
"scd_recurrent_vaso_occlusive_crises",
"sclc_extensive_stage",
"sclc_limited_stage",
"sickle_cell_disease",
"small_cell_lung_cancer",
"small_intestine_cancer",
"t2dm_ckd_risk_reduction",
"t2dm_cv_risk_reduction",
"t2dm_glycaemic_control",
"tmb_h_solid_tumours",
"tmb_h_solid_tumours_cns",
"tmb_h_solid_tumours_ge10",
"tmb_h_solid_tumours_ge13",
"tmb_solid_tumours_patient_10_to_12",
"tnbc_metastatic_first_line",
"tnbc_metastatic_first_line_pembrolizumab_pdl1_cps_10",
"tnbc_metastatic_previously_treated",
"transfusion_dependent_beta_thalassaemia",
"triple_negative_breast_cancer",
"ulcerative_colitis",
"ulcerative_colitis_moderately_to_severely_active",
"urothelial_carcinoma",
"urothelial_metastatic_with_enfortumab_vedotin",
"uveitis",
"vitiligo",
"warm_autoimmune_haemolytic_anaemia",
"weight_management"
],
"type": "string",
"description": "Required for P2: one indication from the published list. allergic_fungal_rhinosinusitis: allergic fungal rhinosinusitis; alopecia_areata: alopecia areata; alveolar_soft_part_sarcoma: alveolar soft part sarcoma; ankylosing_spondylitis: ankylosing spondylitis (radiographic axial spondyloarthritis); asthma: asthma; asthma_moderate_to_severe_add_on_type2_eosinophilic: add-on maintenance treatment of moderate-to-severe asthma, type 2 or eosinophilic phenotype; atopic_dermatitis: atopic dermatitis; atopic_dermatitis_moderate_to_severe_systemic_candidates: moderate-to-severe atopic dermatitis in candidates for systemic therapy; atypical_haemolytic_uraemic_syndrome: atypical haemolytic uraemic syndrome (aHUS); basal_cell_carcinoma: basal cell carcinoma; biliary_tract_cancer: biliary tract cancer; breast_cancer: breast cancer; breast_her2_low_metastatic: metastatic HER2-low breast cancer; breast_her2_positive_metastatic: metastatic HER2-positive breast cancer; breast_her2_positive_metastatic_first_line_pertuzumab: first-line metastatic HER2-positive breast cancer, in combination with pertuzumab; breast_her2_positive_neoadjuvant: neoadjuvant treatment of HER2-positive breast cancer; breast_hr_pos_her2_neg_adjuvant_aromatase_inhibitor_lhrh: adjuvant HR-positive, HER2-negative early breast cancer: aromatase inhibitor with an LHRH agonist; breast_hr_pos_her2_neg_metastatic_initial_endocrine_ai_lhrh: metastatic HR-positive, HER2-negative breast cancer: aromatase inhibitor, initial endocrine therapy, LHRH agonist; breast_hr_positive_her2_negative_adjuvant: adjuvant treatment of HR-positive, HER2-negative early breast cancer; breast_hr_positive_her2_negative_adjuvant_aromatase_inhibitor: adjuvant treatment of HR-positive, HER2-negative early breast cancer, with an aromatase inhibitor; breast_hr_positive_her2_negative_metastatic: metastatic hormone receptor-positive, HER2-negative breast cancer; breast_hr_positive_her2_negative_metastatic_aromatase_inhibitor: metastatic HR-positive, HER2-negative breast cancer, with an aromatase inhibitor; breast_hr_positive_her2_negative_metastatic_initial_endocrine_ai: metastatic HR-positive, HER2-negative breast cancer, with an aromatase inhibitor as initial endocrine-based therapy; breast_hr_positive_her2_ultralow_metastatic: metastatic hormone receptor-positive, HER2-ultralow breast cancer; bullous_pemphigoid: bullous pemphigoid; c3_glomerulopathy: C3 glomerulopathy (C3G); cervical_cancer: cervical cancer; chronic_inflammatory_demyelinating_polyneuropathy: chronic inflammatory demyelinating polyneuropathy (CIDP); chronic_obstructive_pulmonary_disease: chronic obstructive pulmonary disease (COPD); chronic_rhinosinusitis_with_nasal_polyps: chronic rhinosinusitis with nasal polyps; chronic_spontaneous_urticaria: chronic spontaneous urticaria; classical_hodgkin_lymphoma: classical Hodgkin lymphoma; colon_cancer: colon cancer; colorectal_cancer: colorectal cancer; crc_msi_h_dmmr_metastatic_first_line_monotherapy: first-line metastatic MSI-H or dMMR colorectal cancer, monotherapy; crohns_disease: Crohn’s disease; crohns_disease_moderately_to_severely_active: moderately to severely active Crohn’s disease; cutaneous_squamous_cell_carcinoma: cutaneous squamous cell carcinoma; cv_risk_reduction_obesity: reducing the risk of major adverse cardiovascular events; dmd_ambulatory: Duchenne muscular dystrophy, ambulatory patients; dmd_ambulatory_confirmed_mutation: Duchenne muscular dystrophy with a confirmed mutation in the DMD gene, ambulatory patients; dmd_non_ambulatory: Duchenne muscular dystrophy, non-ambulatory patients; dmd_non_ambulatory_confirmed_mutation: Duchenne muscular dystrophy with a confirmed mutation in the DMD gene, non-ambulatory patients; duchenne_muscular_dystrophy: Duchenne muscular dystrophy (DMD); early_alzheimers_disease: early Alzheimer’s disease (mild cognitive impairment or mild dementia stage); early_alzheimers_disease_amyloid_confirmed: early Alzheimer’s disease with confirmed amyloid pathology; early_alzheimers_disease_apoe4_noncarrier_or_heterozygote: early Alzheimer’s disease in ApoE ε4 non-carriers or heterozygotes, amyloid confirmed; endometrial_carcinoma: endometrial carcinoma; endometrial_msi_h_dmmr_previously_treated_monotherapy: advanced MSI-H or dMMR endometrial carcinoma after prior therapy, monotherapy; endometrial_pmmr_previously_treated_with_lenvatinib: advanced pMMR or non-MSI-H endometrial carcinoma after prior therapy, with lenvatinib; enthesitis_related_arthritis: enthesitis-related arthritis; eosinophilic_oesophagitis: eosinophilic oesophagitis; gastric_cancer: gastric or gastro-oesophageal junction cancer; gastric_her2_negative_first_line_with_chemotherapy_pdl1_cps_1: first-line HER2-negative gastric or GEJ adenocarcinoma, with chemotherapy, PD-L1 CPS at least 1; gastric_her2_negative_first_line_with_chemotherapy_pdl1_tap_5: first-line HER2-negative gastric or GEJ adenocarcinoma, with chemotherapy, PD-L1 TAP score at least 5%; generalised_myasthenia_gravis: generalised myasthenia gravis (gMG); giant_cell_arteritis: giant cell arteritis; gmg_achr_antibody_positive: generalised myasthenia gravis, anti-AChR antibody-positive; gmg_achr_antibody_positive_add_on_standard_therapy: gMG, anti-AChR antibody-positive, as an add-on to standard therapy; gmg_musk_antibody_positive: generalised myasthenia gravis, anti-MuSK antibody-positive; gmg_musk_antibody_positive_add_on_standard_therapy: gMG, anti-MuSK antibody-positive, as an add-on to standard therapy; gmg_seronegative: generalised myasthenia gravis, seronegative (neither anti-AChR nor anti-MuSK antibody-positive); hcc_first_line_with_ipilimumab: first-line unresectable or advanced hepatocellular carcinoma, with ipilimumab; head_and_neck_squamous_cell_carcinoma: head and neck squamous cell carcinoma; hepatocellular_carcinoma: hepatocellular carcinoma; her2_positive_solid_tumours: HER2-positive solid tumours (tumour-agnostic); hidradenitis_suppurativa: hidradenitis suppurativa; hnscc_metastatic_first_line_monotherapy_pdl1_cps_1: first-line metastatic HNSCC, monotherapy, PD-L1 CPS at least 1; iga_nephropathy: immunoglobulin A nephropathy (IgAN); immune_complex_mpgn: primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN); malignant_pleural_mesothelioma: malignant pleural mesothelioma; mash_with_fibrosis: metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis; melanoma: melanoma; melanoma_adjuvant: adjuvant treatment of resected melanoma; melanoma_metastatic: metastatic melanoma; melanoma_metastatic_with_ipilimumab: metastatic melanoma, in combination with ipilimumab; merkel_cell_carcinoma: Merkel cell carcinoma; msi_h_dmmr_solid_tumours: MSI-H or dMMR solid tumours (tumour-agnostic); nasopharyngeal_carcinoma: nasopharyngeal carcinoma; neuromyelitis_optica_spectrum_disorder: neuromyelitis optica spectrum disorder (NMOSD); non_radiographic_axial_spondyloarthritis: non-radiographic axial spondyloarthritis; non_small_cell_lung_cancer: non-small cell lung cancer (NSCLC); nsclc_adjuvant: adjuvant treatment of resected NSCLC; nsclc_advanced_first_line_monotherapy_platinum_ineligible: first-line advanced NSCLC, monotherapy, ineligible for platinum-based therapy; nsclc_early_stage_monotherapy: early-stage NSCLC, monotherapy; nsclc_metastatic_after_platinum_monotherapy: metastatic NSCLC after platinum-containing chemotherapy, monotherapy; nsclc_metastatic_first_line_monotherapy_pdl1_cps_1: first-line metastatic NSCLC, monotherapy, PD-L1 combined positive score at least 1, no EGFR or ALK aberration; nsclc_metastatic_first_line_monotherapy_pdl1_ic_10: first-line metastatic NSCLC, monotherapy, PD-L1 immune cell score at least 10%, no EGFR or ALK aberration; nsclc_metastatic_first_line_monotherapy_pdl1_tps_1: first-line metastatic NSCLC, monotherapy, PD-L1 TPS at least 1%, no EGFR or ALK aberration; nsclc_metastatic_first_line_monotherapy_pdl1_tps_50: first-line metastatic NSCLC, monotherapy, PD-L1 TPS at least 50%, no EGFR or ALK aberration; nsclc_metastatic_first_line_nonsquamous_with_chemotherapy: first-line metastatic non-squamous NSCLC, with chemotherapy, no EGFR or ALK aberration; nsclc_metastatic_first_line_squamous_with_chemotherapy: first-line metastatic squamous NSCLC, with chemotherapy; nsclc_metastatic_first_line_with_chemotherapy_pdl1_below_1: first-line metastatic NSCLC, with chemotherapy, PD-L1 tumour proportion score below 1%, no EGFR or ALK aberration; nsclc_metastatic_first_line_with_chemotherapy_pdl1_tps_1: first-line metastatic NSCLC, with chemotherapy, PD-L1 tumour proportion score at least 1%, no EGFR or ALK aberration; nsclc_metastatic_first_line_with_ipilimumab_pdl1: first-line metastatic NSCLC, with ipilimumab, PD-L1 at least 1%, no EGFR or ALK aberration; nsclc_metastatic_with_tremelimumab_alone: metastatic NSCLC, with tremelimumab and no chemotherapy; nsclc_metastatic_with_tremelimumab_and_chemotherapy: metastatic NSCLC, with tremelimumab and platinum-based chemotherapy, no EGFR or ALK aberration; nsclc_monotherapy_pdl1_below_1: unresectable locally advanced NSCLC, monotherapy, PD-L1 tumour proportion score below 1%; nsclc_resectable_large_or_node_positive_adjuvant_monotherapy: resectable NSCLC of at least 4 cm and/or node positive, adjuvant single agent alone; nsclc_resectable_large_or_node_positive_neoadjuvant_chemotherapy: resectable NSCLC of at least 4 cm and/or node positive, neoadjuvant chemotherapy alone; nsclc_resectable_large_or_node_positive_perioperative: resectable NSCLC of at least 4 cm and/or node positive, perioperative, no EGFR or ALK aberration; nsclc_resectable_small_node_negative_perioperative: resectable NSCLC under 4 cm and node negative, neoadjuvant chemotherapy then adjuvant single agent; nsclc_unresectable_stage_iii_monotherapy_after_chemoradiation: unresectable stage III NSCLC, monotherapy, disease not progressed after platinum-based chemoradiation; oesophageal_cancer: oesophageal cancer; osa_with_obesity: obstructive sleep apnoea; ovarian_cancer: ovarian, fallopian tube or primary peritoneal cancer; paroxysmal_nocturnal_haemoglobinuria: paroxysmal nocturnal haemoglobinuria (PNH); plaque_psoriasis: plaque psoriasis; plaque_psoriasis_moderate_to_severe_systemic_candidates: moderate-to-severe plaque psoriasis in candidates for systemic therapy; polyarticular_juvenile_idiopathic_arthritis: polyarticular juvenile idiopathic arthritis; primary_mediastinal_large_b_cell_lymphoma: primary mediastinal large B-cell lymphoma; prurigo_nodularis: prurigo nodularis; psoriatic_arthritis: psoriatic arthritis; psoriatic_arthritis_active: active psoriatic arthritis; rcc_adjuvant_monotherapy: adjuvant treatment of renal cell carcinoma after nephrectomy, monotherapy; rcc_advanced_first_line_with_axitinib: first-line advanced renal cell carcinoma, with axitinib; rcc_advanced_first_line_with_lenvatinib: first-line advanced renal cell carcinoma, with lenvatinib; renal_cell_carcinoma: renal cell carcinoma; rheumatoid_arthritis: rheumatoid arthritis; rheumatoid_arthritis_moderately_to_severely_active: moderately to severely active rheumatoid arthritis; scd_recurrent_vaso_occlusive_crises: sickle cell disease with recurrent vaso-occlusive crises; sclc_extensive_stage: extensive-stage small cell lung cancer; sclc_limited_stage: limited-stage small cell lung cancer; sickle_cell_disease: sickle cell disease (SCD); small_cell_lung_cancer: small cell lung cancer; small_intestine_cancer: small intestine cancer; t2dm_ckd_risk_reduction: reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death; t2dm_cv_risk_reduction: reducing the risk of major adverse cardiovascular events; t2dm_glycaemic_control: glycaemic control in type 2 diabetes; tmb_h_solid_tumours: TMB-H solid tumours (tumour-agnostic); tmb_h_solid_tumours_cns: TMB-H solid tumours that are central nervous system cancers; tmb_h_solid_tumours_ge10: TMB-H solid tumours at 10 or more mutations per megabase; tmb_h_solid_tumours_ge13: TMB-H solid tumours at 13 or more mutations per megabase; tmb_solid_tumours_patient_10_to_12: a solid tumour with 10 to 12 mutations per megabase; tnbc_metastatic_first_line: first-line metastatic triple-negative breast cancer; tnbc_metastatic_first_line_pembrolizumab_pdl1_cps_10: first-line metastatic TNBC, with pembrolizumab, PD-L1 CPS at least 10; tnbc_metastatic_previously_treated: previously treated metastatic triple-negative breast cancer; transfusion_dependent_beta_thalassaemia: transfusion-dependent beta-thalassaemia (TDT); triple_negative_breast_cancer: triple-negative breast cancer; ulcerative_colitis: ulcerative colitis; ulcerative_colitis_moderately_to_severely_active: moderately to severely active ulcerative colitis; urothelial_carcinoma: urothelial carcinoma, including bladder cancer; urothelial_metastatic_with_enfortumab_vedotin: metastatic urothelial carcinoma, with enfortumab vedotin; uveitis: non-infectious uveitis; vitiligo: vitiligo; warm_autoimmune_haemolytic_anaemia: warm autoimmune haemolytic anaemia (wAIHA); weight_management: weight management."
},
"proposition": {
"enum": [
"P1",
"P2"
],
"type": "string",
"description": "P1: registered or authorised in the market. P2: authorised for an indication."
},
"populationMinAgeYears": {
"type": "integer",
"maximum": 120,
"minimum": 0,
"description": "Optional for P2: the youngest age the claim says the indication covers."
}
},
"additionalProperties": false
},
"outputSchema": {
"type": "object",
"required": [
"status",
"relation",
"summary",
"records",
"unresolved",
"scope"
],
"properties": {
"notes": {
"type": "array"
},
"scope": {
"type": "object"
},
"status": {
"enum": [
"settled",
"settling_record_identified",
"supported_attested",
"reference_only",
"unresolved"
],
"type": "string"
},
"records": {
"type": "array"
},
"summary": {
"type": "string"
},
"relation": {
"enum": [
"agrees",
"agrees_narrower",
"disagrees",
"insufficient"
],
"type": "string"
},
"abstention": {
"type": [
"object",
"null"
],
"properties": {
"code": {
"enum": [
"insufficient_evidence",
"authority_inaccessible",
"conflicting_records",
"stale_evidence",
"unsupported_claim_type",
"snapshot_only"
],
"type": "string"
},
"route": {
"enum": [
"search_further",
"retry_later",
"request_human_review",
"stop"
],
"type": "string"
},
"meaning": {
"type": "string"
}
},
"description": "Null when settled. Otherwise one reason code: insufficient_evidence (route search_further): No held record settles the claim for this market and date. authority_inaccessible (route retry_later): The record that would decide the claim could not be read just now; retryAfter gives when it may be read. conflicting_records (route request_human_review): Records held disagree about the claim. stale_evidence (route search_further): The evidence held is out of date for the date asked. unsupported_claim_type (route stop): The claim is not one this service assesses: its market, proposition or indication is not supported. snapshot_only (route search_further): A past authoritative capture is held, but the current record is not confirmed."
},
"comparison": {
"type": "array"
},
"inspection": {
"type": "object"
},
"unresolved": {
"type": "array"
},
"indicationScope": {
"type": [
"object",
"null"
],
"description": "Where the regulator recorded that a use is not a separate indication, though its benefit is stated in the product information and the use is covered by an existing indication: the three apart, with the document."
},
"competentAuthorities": {
"type": "array"
}
}
},
"annotations": {
"title": "Is a medicine approved in a market?",
"readOnlyHint": true,
"openWorldHint": true,
"idempotentHint": true,
"destructiveHint": false
}
}Answers what a drug's or medicine's official FDA label (the US prescribing information) or EU summary of product characteristics (SmPC) says, and its FDA approval or EU authorisation facts, today or on a past date: what it is approved or authorised for and in whom, dosage, contraindications, the boxed warning, warnings and precautions, use in pregnancy, breastfeeding, children and older people, adverse reactions, interactions, overdose, pharmacology, storage, and the label's version history. For the US it reads the application holder's label as published on DailyMed and the FDA's approval record on Drugs@FDA; for the EU it reads each SmPC in the European Commission's product information as published by the EMA, and the EMA's medicines data. Each answer gives the record's own words for the section asked, with the section number, the document's version, its effective date, the SHA-256 of the exact document read and its address, and the source to acknowledge. Where a product information holds several SmPCs (strengths or forms), each is given apart. The indications text is the record's statement; whether a particular use falls within it is not decided, except for an indication from the published list, where the reference lookup's own answer is given beside it. Where the record cannot be read, matched or confirmed for the date, no text is given: the answer is unresolved, with one reason code (insufficient_evidence, authority_inaccessible, conflicting_records, stale_evidence, unsupported_claim_type, snapshot_only) and its meaning.
| Parameter | Type | Description |
|---|---|---|
| date | string | The date the question is about, YYYY-MM-DD. Defaults to today (UTC). |
| since | string | Optional, with topic history and section: show what changed in the section between the version published on this date (YYYY-MM-DD) and the current one. |
| topic * | string | What to read. approval: whether and since when it is approved or authorised, its current status, application or product number and holder; indications: what it is approved or authorised for, and in whom (US section 1; SmPC 4.1); dosage: dose and how it is given (US section 2; SmPC 4.2); dosage_forms… |
| market * | string | US (FDA) or EU (centrally authorised medicines). |
| product | string | Optional: a strength or form as the label names it (for example 395 mg, or solution for injection), to choose among several SmPCs or labels. |
| section | string | Optional, with topic history and since: the section whose change is shown. |
| medicine * | string | The brand or active substance name, exactly (for example Jardiance or empagliflozin). |
| indication | string | Optional, with topic indications: an indication from the published list, to add the reference lookup's own answer for it. |
| application | string | Optional: the exact application, a US NDA, ANDA or BLA number (for example ANDA078071) or an EMA product number (for example EMEA/H/C/002677), so a generic or a duplicate authorisation is answered for itself. |
{
"name": "read_drug_label_fda_eu",
"title": "What does a drug's FDA or EU label say?",
"description": "Answers what a drug's or medicine's official FDA label (the US prescribing information) or EU summary of product characteristics (SmPC) says, and its FDA approval or EU authorisation facts, today or on a past date: what it is approved or authorised for and in whom, dosage, contraindications, the boxed warning, warnings and precautions, use in pregnancy, breastfeeding, children and older people, adverse reactions, interactions, overdose, pharmacology, storage, and the label's version history. For the US it reads the application holder's label as published on DailyMed and the FDA's approval record on Drugs@FDA; for the EU it reads each SmPC in the European Commission's product information as published by the EMA, and the EMA's medicines data. Each answer gives the record's own words for the section asked, with the section number, the document's version, its effective date, the SHA-256 of the exact document read and its address, and the source to acknowledge. Where a product information holds several SmPCs (strengths or forms), each is given apart. The indications text is the record's statement; whether a particular use falls within it is not decided, except for an indication from the published list, where the reference lookup's own answer is given beside it. Where the record cannot be read, matched or confirmed for the date, no text is given: the answer is unresolved, with one reason code (insufficient_evidence, authority_inaccessible, conflicting_records, stale_evidence, unsupported_claim_type, snapshot_only) and its meaning.",
"inputSchema": {
"type": "object",
"required": [
"medicine",
"market",
"topic"
],
"properties": {
"date": {
"type": "string",
"description": "The date the question is about, YYYY-MM-DD. Defaults to today (UTC)."
},
"since": {
"type": "string",
"description": "Optional, with topic history and section: show what changed in the section between the version published on this date (YYYY-MM-DD) and the current one."
},
"topic": {
"enum": [
"approval",
"indications",
"dosage",
"dosage_forms",
"contraindications",
"boxed_warning",
"warnings_precautions",
"adverse_reactions",
"interactions",
"specific_populations",
"pregnancy",
"lactation",
"pediatric",
"geriatric",
"overdose",
"pharmacodynamics",
"pharmacokinetics",
"pharmaceutical_particulars",
"history"
],
"type": "string",
"description": "What to read. approval: whether and since when it is approved or authorised, its current status, application or product number and holder; indications: what it is approved or authorised for, and in whom (US section 1; SmPC 4.1); dosage: dose and how it is given (US section 2; SmPC 4.2); dosage_forms: dosage forms and strengths (US section 3; SmPC 2 and 3); contraindications: contraindications (US section 4; SmPC 4.3); boxed_warning: the boxed warning (US only; the SmPC has none); warnings_precautions: warnings and precautions (US section 5; SmPC 4.4); adverse_reactions: adverse reactions (US section 6; SmPC 4.8); interactions: interactions (US section 7; SmPC 4.5); specific_populations: use in specific populations (US section 8; SmPC 4.6, with 4.2 for the paediatric and elderly populations); pregnancy: pregnancy (US 8.1; SmPC 4.6); lactation: lactation and breastfeeding (US 8.2; SmPC 4.6); pediatric: use in children (US 8.4; SmPC 4.1 and 4.2); geriatric: use in older people (US 8.5; SmPC 4.2); overdose: overdose (US section 10; SmPC 4.9); pharmacodynamics: mechanism of action and pharmacodynamics (US 12.1 and 12.2; SmPC 5.1); pharmacokinetics: pharmacokinetics (US 12.3; SmPC 5.2); pharmaceutical_particulars: storage, shelf life, excipients and container (US section 16; SmPC 6.1 to 6.6); history: the label's published versions and dates, and what changed in a section between two versions where both are published."
},
"market": {
"enum": [
"US",
"EU"
],
"type": "string",
"description": "US (FDA) or EU (centrally authorised medicines)."
},
"product": {
"type": "string",
"description": "Optional: a strength or form as the label names it (for example 395 mg, or solution for injection), to choose among several SmPCs or labels."
},
"section": {
"enum": [
"indications",
"dosage",
"dosage_forms",
"contraindications",
"boxed_warning",
"warnings_precautions",
"adverse_reactions",
"interactions",
"specific_populations",
"pregnancy",
"lactation",
"pediatric",
"geriatric",
"overdose",
"pharmacodynamics",
"pharmacokinetics",
"pharmaceutical_particulars"
],
"type": "string",
"description": "Optional, with topic history and since: the section whose change is shown."
},
"medicine": {
"type": "string",
"description": "The brand or active substance name, exactly (for example Jardiance or empagliflozin)."
},
"indication": {
"enum": [
"allergic_fungal_rhinosinusitis",
"alopecia_areata",
"alveolar_soft_part_sarcoma",
"ankylosing_spondylitis",
"asthma",
"asthma_moderate_to_severe_add_on_type2_eosinophilic",
"atopic_dermatitis",
"atopic_dermatitis_moderate_to_severe_systemic_candidates",
"atypical_haemolytic_uraemic_syndrome",
"basal_cell_carcinoma",
"biliary_tract_cancer",
"breast_cancer",
"breast_her2_low_metastatic",
"breast_her2_positive_metastatic",
"breast_her2_positive_metastatic_first_line_pertuzumab",
"breast_her2_positive_neoadjuvant",
"breast_hr_pos_her2_neg_adjuvant_aromatase_inhibitor_lhrh",
"breast_hr_pos_her2_neg_metastatic_initial_endocrine_ai_lhrh",
"breast_hr_positive_her2_negative_adjuvant",
"breast_hr_positive_her2_negative_adjuvant_aromatase_inhibitor",
"breast_hr_positive_her2_negative_metastatic",
"breast_hr_positive_her2_negative_metastatic_aromatase_inhibitor",
"breast_hr_positive_her2_negative_metastatic_initial_endocrine_ai",
"breast_hr_positive_her2_ultralow_metastatic",
"bullous_pemphigoid",
"c3_glomerulopathy",
"cervical_cancer",
"chronic_inflammatory_demyelinating_polyneuropathy",
"chronic_obstructive_pulmonary_disease",
"chronic_rhinosinusitis_with_nasal_polyps",
"chronic_spontaneous_urticaria",
"classical_hodgkin_lymphoma",
"colon_cancer",
"colorectal_cancer",
"crc_msi_h_dmmr_metastatic_first_line_monotherapy",
"crohns_disease",
"crohns_disease_moderately_to_severely_active",
"cutaneous_squamous_cell_carcinoma",
"cv_risk_reduction_obesity",
"dmd_ambulatory",
"dmd_ambulatory_confirmed_mutation",
"dmd_non_ambulatory",
"dmd_non_ambulatory_confirmed_mutation",
"duchenne_muscular_dystrophy",
"early_alzheimers_disease",
"early_alzheimers_disease_amyloid_confirmed",
"early_alzheimers_disease_apoe4_noncarrier_or_heterozygote",
"endometrial_carcinoma",
"endometrial_msi_h_dmmr_previously_treated_monotherapy",
"endometrial_pmmr_previously_treated_with_lenvatinib",
"enthesitis_related_arthritis",
"eosinophilic_oesophagitis",
"gastric_cancer",
"gastric_her2_negative_first_line_with_chemotherapy_pdl1_cps_1",
"gastric_her2_negative_first_line_with_chemotherapy_pdl1_tap_5",
"generalised_myasthenia_gravis",
"giant_cell_arteritis",
"gmg_achr_antibody_positive",
"gmg_achr_antibody_positive_add_on_standard_therapy",
"gmg_musk_antibody_positive",
"gmg_musk_antibody_positive_add_on_standard_therapy",
"gmg_seronegative",
"hcc_first_line_with_ipilimumab",
"head_and_neck_squamous_cell_carcinoma",
"hepatocellular_carcinoma",
"her2_positive_solid_tumours",
"hidradenitis_suppurativa",
"hnscc_metastatic_first_line_monotherapy_pdl1_cps_1",
"iga_nephropathy",
"immune_complex_mpgn",
"malignant_pleural_mesothelioma",
"mash_with_fibrosis",
"melanoma",
"melanoma_adjuvant",
"melanoma_metastatic",
"melanoma_metastatic_with_ipilimumab",
"merkel_cell_carcinoma",
"msi_h_dmmr_solid_tumours",
"nasopharyngeal_carcinoma",
"neuromyelitis_optica_spectrum_disorder",
"non_radiographic_axial_spondyloarthritis",
"non_small_cell_lung_cancer",
"nsclc_adjuvant",
"nsclc_advanced_first_line_monotherapy_platinum_ineligible",
"nsclc_early_stage_monotherapy",
"nsclc_metastatic_after_platinum_monotherapy",
"nsclc_metastatic_first_line_monotherapy_pdl1_cps_1",
"nsclc_metastatic_first_line_monotherapy_pdl1_ic_10",
"nsclc_metastatic_first_line_monotherapy_pdl1_tps_1",
"nsclc_metastatic_first_line_monotherapy_pdl1_tps_50",
"nsclc_metastatic_first_line_nonsquamous_with_chemotherapy",
"nsclc_metastatic_first_line_squamous_with_chemotherapy",
"nsclc_metastatic_first_line_with_chemotherapy_pdl1_below_1",
"nsclc_metastatic_first_line_with_chemotherapy_pdl1_tps_1",
"nsclc_metastatic_first_line_with_ipilimumab_pdl1",
"nsclc_metastatic_with_tremelimumab_alone",
"nsclc_metastatic_with_tremelimumab_and_chemotherapy",
"nsclc_monotherapy_pdl1_below_1",
"nsclc_resectable_large_or_node_positive_adjuvant_monotherapy",
"nsclc_resectable_large_or_node_positive_neoadjuvant_chemotherapy",
"nsclc_resectable_large_or_node_positive_perioperative",
"nsclc_resectable_small_node_negative_perioperative",
"nsclc_unresectable_stage_iii_monotherapy_after_chemoradiation",
"oesophageal_cancer",
"osa_with_obesity",
"ovarian_cancer",
"paroxysmal_nocturnal_haemoglobinuria",
"plaque_psoriasis",
"plaque_psoriasis_moderate_to_severe_systemic_candidates",
"polyarticular_juvenile_idiopathic_arthritis",
"primary_mediastinal_large_b_cell_lymphoma",
"prurigo_nodularis",
"psoriatic_arthritis",
"psoriatic_arthritis_active",
"rcc_adjuvant_monotherapy",
"rcc_advanced_first_line_with_axitinib",
"rcc_advanced_first_line_with_lenvatinib",
"renal_cell_carcinoma",
"rheumatoid_arthritis",
"rheumatoid_arthritis_moderately_to_severely_active",
"scd_recurrent_vaso_occlusive_crises",
"sclc_extensive_stage",
"sclc_limited_stage",
"sickle_cell_disease",
"small_cell_lung_cancer",
"small_intestine_cancer",
"t2dm_ckd_risk_reduction",
"t2dm_cv_risk_reduction",
"t2dm_glycaemic_control",
"tmb_h_solid_tumours",
"tmb_h_solid_tumours_cns",
"tmb_h_solid_tumours_ge10",
"tmb_h_solid_tumours_ge13",
"tmb_solid_tumours_patient_10_to_12",
"tnbc_metastatic_first_line",
"tnbc_metastatic_first_line_pembrolizumab_pdl1_cps_10",
"tnbc_metastatic_previously_treated",
"transfusion_dependent_beta_thalassaemia",
"triple_negative_breast_cancer",
"ulcerative_colitis",
"ulcerative_colitis_moderately_to_severely_active",
"urothelial_carcinoma",
"urothelial_metastatic_with_enfortumab_vedotin",
"uveitis",
"vitiligo",
"warm_autoimmune_haemolytic_anaemia",
"weight_management"
],
"type": "string",
"description": "Optional, with topic indications: an indication from the published list, to add the reference lookup's own answer for it."
},
"application": {
"type": "string",
"description": "Optional: the exact application, a US NDA, ANDA or BLA number (for example ANDA078071) or an EMA product number (for example EMEA/H/C/002677), so a generic or a duplicate authorisation is answered for itself."
}
},
"additionalProperties": false
},
"outputSchema": {
"type": "object",
"required": [
"status",
"summary",
"records",
"unresolved",
"attribution"
],
"properties": {
"status": {
"enum": [
"record_text",
"record_facts",
"unresolved"
],
"type": "string"
},
"records": {
"type": "array"
},
"summary": {
"type": "string"
},
"verdict": {
"type": [
"object",
"null"
]
},
"abstention": {
"type": [
"object",
"null"
]
},
"decidesUse": {
"type": "boolean"
},
"unresolved": {
"type": "array"
},
"attribution": {
"type": "array"
}
}
},
"annotations": {
"title": "What does a drug's FDA or EU label say?",
"readOnlyHint": true,
"openWorldHint": true,
"idempotentHint": true,
"destructiveHint": false
}
}For one ruling identifier (ACPREC-YYYY-NNNN): what was decided about an evidence conflict, why, on which records, its status now (settled, unresolved or superseded) and its RFC 3161 timestamp where one has been issued, together with a fresh lookup of the current governing record for the ruling's medicine, market and date where the ruling names one. A ruling is not evidence and decides no claim today; the current governing record does, and the ruling records only how the earlier conflict was decided. Where no current record is held, the answer names the competent authority and where its own record is published.
| Parameter | Type | Description |
|---|---|---|
| id * | string | The ruling identifier, for example ACPREC-2026-0001. |
| date | string | The date to resolve the current record for, YYYY-MM-DD. Defaults to today (UTC). |
{
"name": "lookup_precedent_ruling",
"title": "A numbered AlphaCitation ruling on an evidence conflict",
"description": "For one ruling identifier (ACPREC-YYYY-NNNN): what was decided about an evidence conflict, why, on which records, its status now (settled, unresolved or superseded) and its RFC 3161 timestamp where one has been issued, together with a fresh lookup of the current governing record for the ruling's medicine, market and date where the ruling names one. A ruling is not evidence and decides no claim today; the current governing record does, and the ruling records only how the earlier conflict was decided. Where no current record is held, the answer names the competent authority and where its own record is published.",
"inputSchema": {
"type": "object",
"required": [
"id"
],
"properties": {
"id": {
"type": "string",
"pattern": "^ACPREC-[0-9]{4}-[0-9]{4}$",
"description": "The ruling identifier, for example ACPREC-2026-0001."
},
"date": {
"type": "string",
"description": "The date to resolve the current record for, YYYY-MM-DD. Defaults to today (UTC)."
}
},
"additionalProperties": false
},
"annotations": {
"title": "AlphaCitation precedent ruling",
"readOnlyHint": true,
"openWorldHint": true,
"idempotentHint": true,
"destructiveHint": false
}
}Use check_drug_approval_fda_eu (the same lookup is also listed as lookup_medicine_evidence) before stating whether a drug or medicine is approved, registered or authorised, or approved for an indication, in a market, today or on a past date. For the US and the EU it returns the current FDA or European Commission record with its date and pointer URL, which memory and web pages may not reflect. Answer from the record the result relies on and cite its pointer URL. Do not present settling_record_identified, supported_attested, reference_only or unresolved as settled. Use read_drug_label_fda_eu for what a drug's FDA label or EU SmPC says: its dose, contraindications, boxed warning, warnings, use in pregnancy or children, any named section, or its version history. Use lookup_precedent_ruling when a user gives or asks about an AlphaCitation ruling by its identifier (ACPREC-YYYY-NNNN). A ruling records how an earlier evidence conflict was decided and settles no claim today: answer from the current governing record returned beside it. Which record settles a claim is decided under the AlphaCitation Evidence-Authority Standard (EAS-Prime, https://alphacitation.com/standards/evidence-authority).
Names, descriptions and schemas were written by the server and are shown as data.
Shared addresses on big platforms (Cloudflare, Vercel and the like) put unrelated servers together; those are marked shared_infrastructure. A match is a pivot, not a link between operators.